Home

ZURICH (Reuters) - Roche's top-selling Avastin helps patients with the most common form of lung cancer live longer than any other treatment, the Swiss drugmaker said on Friday, giving the drug a boost after a slew of setbacks. A late-stage trial showed first-line Avastin-based therapy in advanced non-small cell adenocarcinoma of the lung resulted in a median overall survival of ...

Bayer HealthCare and Onyx Pharmaceuticals Inc. said Monday their cancer treatment Nexavar failed to boost survival in a clinical study involving patients with a certain type of advanced lung cancer. Nexavar, which is on the market as a treatment for liver cancer and kidney ...

Abraxis BioScience said data from a late-stage study in lung cancer patients showed its drug Abraxane worked better than Taxol when given in combination with a chemotherapy drug. Abraxane is a chemotherapy agent that combines paclitaxel, also known by the brand name Taxol, with a naturally-occurring ...

A new experimental drug helps shrink tumors in lung cancer patients with a specific form of genetic alteration, according to results from a clinical trial unveiled Saturday. The Pfizer Inc. drug crizotinib shrank tumors in patients with advanced non-small cell lung cancer (NSCLC) with a specific gene alteration of an enzyme implicated in cancer cell growth, known as anaplastic lymphoma ...

Doctors are reporting unusually high success rates from early tests of an experimental lung cancer drug. The drug, called crizotinib, (crih-ZAH-tin-ib), is made by Pfizer Inc. It targets a gene that is found in about 4 percent of lung cancers, which amounts to 10 ...

NEW YORK (Reuters) - An experimental drug being developed by Pfizer Inc that targets a specific gene mutation demonstrated impressive anti-tumor activity in patients with advanced non-small cell lung cancer (NSCLC), according to data from a small study presented on Saturday. More than half of the patients treated with the drug, crizotinib, experienced significant tumor shrinkage, and nearly 90 percent had ...

WASHINGTON (Reuters) - A drug approved to treat a range of conditions may also work to prevent lung cancer in people who have given up smoking, U.S. researchers reported on Tuesday. The drug, called iloprost, is approved in inhaled forms to treat pulmonary hypertension, when blood pools near the lungs, a connective tissue disease called scleroderma and a nerve condition ...

NEW YORK (Reuters Health) - Almost twice as many Swedes as Britons survive the first five years after a lung cancer diagnosis, a new report reveals. By examining nationwide cancer registries and death certificates in three countries, doctors found that survival rates for men dropped from 11.3 percent in Sweden, to 9.3 percent in Norway, to 6.5 percent ...

WASHINGTON (Reuters) - Researchers said they helped advanced lung cancer patients fare better by matching their tumors to targeted drugs, in what they said is the first significant trial to show it is possible to choose the best drug for an individual patient. They tested four so-called targeted therapies in patients with specific biomarkers -- mutations that the drugs were designed to ...

WASHINGTON (Reuters) - Researchers have identified a group of genes that are especially active in lung cancer patients -- even in healthy tissue -- and said they may be used to predict which smokers will eventually develop lung cancer. And, they said, a natural supplement derived from food that is being tested to prevent lung cancer appears to halt the precancerous changes. "Even ...